Zynerba

June 27, 2017

Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program

ZYN001 is a synthetic pro‑drug of THC in a state-of-the-art drug-adhesive … ZYN002, the Company's CBD gel, is the first and only…

Read More

June 2, 2017

Better Know a Marijuana Stock: Zynerba Pharmaceuticals

However, there are dozens of marijuana stocks for investors to choose from. … For those who may not recall, an oral CBD-based…

Read More

February 23, 2017

Maxim Group Starts Zynerba Pharmaceuticals (ZYNE) at Buy

2017 could be a transformational year for Zynerba, as three ongoing phase II trials for lead cannabis-based candidate, ZYN002 cannabidiol (CBD) gel ……

Read More

February 19, 2017

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) One of the More Legit Marijuana Companies

ZYN002 CBD gel is the first and only patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery….

Read More

January 9, 2017

Zynerba Thesis Continues To Play Out As Management Executes

… psychoactive effects, GI distress, and reducing drug interactions patients and doctors would be more likely to prefer ZYN002 over oral CBD…

Read More

December 13, 2016

Best Stocks of 2017: Zynerba Pharmaceuticals Inc (ZYNE) Stock Is a Perfect Prescription

This is the cleaner side of marijuana. … defining compounds, cannabinoid (CBD) and tetrahydrocannabinol (THC), then deliver to them to patients as…

Read More